We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed at $203.53 in the latest trading session, marking a -0.63% move from the prior day. This change lagged the S&P 500's 0.16% gain on the day.
Coming into today, shares of the vaccine maker had lost 14.13% in the past month. In that same time, the Medical sector lost 4.94%, while the S&P 500 lost 3.32%.
Investors will be hoping for strength from NVAX as it approaches its next earnings release. On that day, NVAX is projected to report earnings of -$4.04 per share, which would represent a year-over-year decline of 25.86%. Our most recent consensus estimate is calling for quarterly revenue of $306.8 million, up 95.39% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$8.37 per share and revenue of $1.77 billion. These totals would mark changes of -15.13% and +273.17%, respectively, from last year.
Any recent changes to analyst estimates for NVAX should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.86% lower. NVAX is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 178, putting it in the bottom 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
Novavax (NVAX - Free Report) closed at $203.53 in the latest trading session, marking a -0.63% move from the prior day. This change lagged the S&P 500's 0.16% gain on the day.
Coming into today, shares of the vaccine maker had lost 14.13% in the past month. In that same time, the Medical sector lost 4.94%, while the S&P 500 lost 3.32%.
Investors will be hoping for strength from NVAX as it approaches its next earnings release. On that day, NVAX is projected to report earnings of -$4.04 per share, which would represent a year-over-year decline of 25.86%. Our most recent consensus estimate is calling for quarterly revenue of $306.8 million, up 95.39% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$8.37 per share and revenue of $1.77 billion. These totals would mark changes of -15.13% and +273.17%, respectively, from last year.
Any recent changes to analyst estimates for NVAX should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.86% lower. NVAX is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 178, putting it in the bottom 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.